超越药物排石治疗:输尿管结石支持性排石方案的演变
单中心连续年度比较研究纳入723例单侧<1 cm输尿管结石患者,比较初始年他索罗辛药物排石治疗(MET)与次年取消他索罗辛的支持性排石(SSP)方案。SSP组尝试排石率从65%升至74%,总体手术率从51%降至40%,尝试排石者手术率两组无显著差异。取消他索罗辛未损害排石。
要点
- 取消他索罗辛后尝试排石率从65%升至74%(P<0.016)。
- 总体手术率从MET组51%降至SSP组40%(P=0.003)。
- 尝试排石者手术率MET组26% vs SSP组19%(P=0.066)。
核心结论
- 从临床方案中取消他索罗辛未损害尝试排石患者的结石排出。
研究设计与样本
- 单中心连续年度比较研究,比较急诊出院后至结石门诊就诊的单侧<1 cm输尿管结石患者。
- 共723例患者,初始年MET组360例,次年SSP组363例。
- 主要结局为初始门诊就诊后90天内结石手术率。
主要发现
- 尝试排石率从初始年65%升至次年74%(P<0.016)。
- 尝试排石患者中他索罗辛处方率从84%降至13%(P<0.001)。
- 尝试排石者手术率MET组26%、SSP组19%(P=0.066)。
- 总体手术率MET组51%、SSP组40%(P=0.003)。
- 多变量分析控制年龄、性别和结石负荷后,两种方案在尝试排石率或排石失败率上无差异。
关键数值与推荐
- 未能证明他索罗辛对排石失败有独立效应。
临床怎么用
- 临床方案可考虑取消他索罗辛,转向以症状控制为核心的支持性排石。
- 取消他索罗辛后需关注尝试排石率变化及总体手术率下降趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of removing tamsulosin from standardized ureteric stone clinical protocols on rate of stone surgery. PARTICIPANTS AND METHODS: We conducted a single-centre, comparison of all patients with unilateral, <1 cm ureteric stones presenting to a stone clinic after discharge from the emergency department during consecutive years. In the initial year, patients were initially offered medical expulsive therapy (MET) with tamsulosin. In the subsequent year, the protocol was modified to focus on symptom control without tamsulosin; this was termed 'supported stone passage' (SSP). The primary outcome was rate of stone surgery within 90 days of the initial clinic encounter. RESULTS: Among 723 patients (360 MET, 363 SSP), the rate of attempted stone passage increased from 65% to 74%, between the initial and the subsequent year (P < 0.016). Tamsulosin prescription in patients to attempting stone passage decreased from 84% to 13% (P < 0.001). In patients attempting stone passage, the rate of stone surgery was 26% in the METand 19% in the SSP group (P = 0.066). The overall surgery rate decreased from 51% in the MET group to 40% in the SSP group (P = 0.003). Multivariable analysis, controlling for age, sex and stone burden, did not demonstrate a difference in either rate of attempting to pass stones or in rate of failure of passage according to care protocol. We were unable to demonstrate an independent effect of tamsulosin on failure of passage. Overall, surgical intervention was less likely in the SSP phase than in the MET phase, with an odds ratio of 0.64 (confidence interval) 0.44-0.91; P = 0.013). CONCLUSIONS: Removing tamsulosin from clinical protocols did not impair stone passage in patients attempting to pass stones.
引用
- Portis AJ, Portis JL, Borofsky MS, et al. Beyond medical expulsive therapy: evolution to supported stone passage for ureteric stones. BJU Int. 2018. PMID: 30019368. doi:10.1111/bju.14491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。